Snellman acted as the Swedish counsel to Charles River Laboratories International, Inc. in the acquisition of Cognate BioServices, Inc,. including its Swedish and British subsidiaries Cobra Biologics, a premier cell and gene therapy contract development and manufacturing organisation. The purchase price amounted to approximately USD 875 million.

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Charles River Laboratories International, Inc. is publicly traded on the New York Stock Exchange.

Snellman’s core team included Richard Åkerman, Nicole Jerad, Douglas Essehorn, Iiris Ikkelä, and Alexander Lindqvist (Private M&A), Jenny Lundberg (Employment), and Elisabeth Vestin and Itai Coleman (IP & Tech).